CD301b/MGL2+单核吞噬细胞驱动自身免疫性心脏瓣膜炎症与纤维化
该研究在K/B.g7自身免疫性小鼠模型中揭示,浸润二尖瓣的CD301b/MGL2+单核吞噬细胞是瓣膜炎症和纤维化的关键驱动者,其通过Syk、TNF、IL-6、VLA-4和VCAM-1等分子发挥作用,且类似细胞存在于人类风湿性心脏病瓣膜中。
要点
- CD301b/MGL2+单核吞噬细胞是自身免疫性二尖瓣病变的关键驱动细胞。
- Syk、TNF、IL-6、VLA-4和VCAM-1是推动瓣膜病变的关键炎症分子。
- 人类风湿性心脏病瓣膜中存在类似细胞,提示临床相关性。
核心结论
- CD301b/MGL2+单核吞噬细胞是K/B.g7小鼠自身免疫性二尖瓣病变的关键驱动者,且存在于人类风湿性心脏病瓣膜中。
- Syk、TNF、IL-6、VLA-4和VCAM-1是驱动该模型二尖瓣病变的关键炎症分子。
研究设计与样本
- 研究采用K/B.g7 T细胞受体转基因小鼠,该模型自发产生系统性自身抗体相关自身免疫,导致完全外显的纤维炎症性二尖瓣病变和关节炎。
- 使用多参数流式细胞术、胞内细胞因子染色和免疫荧光染色表征炎症二尖瓣中的细胞。
- 通过遗传学方法构建CX3CR1或CD301b/MGL2表达单核吞噬细胞被清除的K/B.g7小鼠,并条件性删除CX3CR1表达单核吞噬细胞中的Syk和VLA-4。
- 使用单克隆抗体阻断关键炎症分子,并构建骨髓嵌合体小鼠确定炎症细胞来源及对TNF响应的瓣膜细胞。
- 检查风湿性心脏病患者标本以与人类病理进行关联。
主要发现
- 单核吞噬细胞构成二尖瓣浸润细胞的绝大多数,表达CX3CR1和CD301b/MGL2,类似细胞存在于人类风湿性心脏病瓣膜中。
- 缺乏CX3CR1或清除CD301b/MGL2表达单核吞噬细胞的K/B.g7小鼠免于二尖瓣病变。
- 浸润瓣膜的CD301b/MGL2+单核吞噬细胞表达组织修复分子精氨酸酶-1和抵抗素样分子α,同时也表达促炎细胞因子TNF和IL-6。
- 抗体阻断TNF或IL-6可预防二尖瓣病变;删除CX3CR1表达单核吞噬细胞中的Syk减少其TNF和IL-6产生并预防二尖瓣病变。
- TNF通过瓣膜驻留细胞表达的TNF受体1增加血管细胞黏附分子-1表达;条件性删除CX3CR1表达单核吞噬细胞中的VLA-4可预防二尖瓣病变。
临床怎么用
- 在自身免疫相关二尖瓣病变中,CD301b/MGL2+单核吞噬细胞及其炎症通路(Syk、TNF、IL-6、VLA-4/VCAM-1)可作为潜在干预靶点。
- 该模型中的发现与人类风湿性心脏病瓣膜病理存在关联,提示这些通路可能具有临床转化意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Valvular heart disease is common and affects the mitral valve (MV) most frequently. Despite the prevalence of MV disease (MVD), the cellular and molecular pathways that initiate and perpetuate it are not well understood. METHODS: K/B.g7 T-cell receptor transgenic mice spontaneously develop systemic autoantibody-associated autoimmunity, leading to fully penetrant fibroinflammatory MVD and arthritis. We used multiparameter flow cytometry, intracellular cytokine staining, and immunofluorescent staining to characterize the cells in inflamed K/B.g7 MVs. We used genetic approaches to study the contribution of mononuclear phagocytes (MNPs) to MVD in this model. Specifically, we generated K/B.g7 mice in which either CX3CR1 or CD301b/macrophage galactose N-acetylgalactosamine-specific lectin 2 (MGL2)-expressing MNPs were ablated. Using K/B.g7 mice expressing Cx3Cr1-Cre, we conditionally deleted critical inflammatory molecules from MNPs, including the Fc-receptor signal-transducing tyrosine kinase Syk and the cell adhesion molecule very late antigen-4. We performed complementary studies using monoclonal antibodies to block key inflammatory molecules. We generated bone marrow chimeric mice to define the origin of the inflammatory cells present in the MV and to determine which valve cells respond to the proinflammatory cytokine tumor necrosis factor (TNF). Finally, we examined specimens from patients with rheumatic heart disease to correlate our findings to human pathology. RESULTS: MNPs comprised the vast majority of MV-infiltrating cells; these MNPs expressed CX3CR1 and CD301b/MGL2. Analogous cells were present in human rheumatic heart disease valves. K/B.g7 mice lacking CX3CR1 or in which CD301b/MGL2-expressing MNPs were ablated were protected from MVD. The valve-infiltrating CD301b/MGL2+ MNPs expressed tissue-reparative molecules including arginase-1 and resistin-like molecule α. These MNPs also expressed the proinflammatory cytokines TNF and interleukin-6, and antibody blockade of these cytokines prevented MVD. Deleting Syk from CX3CR1-expressing MNPs reduced their TNF and interleukin-6 production and also prevented MVD. TNF acted through TNF receptor-1 expressed on valve-resident cells to increase the expression of vascular cell adhesion molecule-1. Conditionally deleting the vascular cell adhesion molecule-1 ligand very late antigen-4 from CX3CR1-expressing MNPs prevented MVD. CONCLUSIONS: CD301b/MGL2+ MNPs are key drivers of autoimmune MVD in K/B.g7 mice and are also present in human rheumatic heart disease. We define key inflammatory molecules that drive MVD in this model, including Syk, TNF, interleukin-6, very late antigen-4, and vascular cell adhesion molecule-1.
引用
- Meier LA, Auger JL, Engelson BJ, et al. CD301b/MGL2+ Mononuclear Phagocytes Orchestrate Autoimmune Cardiac Valve Inflammation and Fibrosis. Circulation. 2018. PMID: 29386201. doi:10.1161/CIRCULATIONAHA.117.033144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。